Alliance Global Partners Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $32
Alliance Global Partners analyst Matthew Venezia initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $32.
Stocks · News reference
Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review
FDA accepts Immunome's varegacestat NDA for desmoid tumors, with an April 28, 2027, PDUFA date backed by positive Phase 3 data.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $40 price target.
ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braze and others also fell premarket.
Truist Securities Maintains Buy on Immunome, Raises Price Target to $38
Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price target from $37 to $38.